SEATTLE, May 28, 2021, (MEDGADGET) — Heparin is a drug and a naturally occurring glycosaminoglycan that is also known as unfractionated heparin (UFH). Heparin is an anticoagulant that is used to treat a variety of conditions including acute coronary syndrome, atrial fibrillation (AF), venous thromboembolism (VTE), cardiopulmonary bypass for cardiac surgery, and the Extracorporeal Membrane Oxygenation (ECMO) circuit for extracorporeal life support, hemofiltration, and indwelling central or peripheral venous catheters.
High prevalence of AF is expected to boost growth of Europe heparin market over the forecast period. According to the British Heart Foundation’s (BHF) Heart and Circulatory Disease Statistics 2019, released in partnership with the University of Birmingham’s Institute of Applied Health Science, 185,423 men and 155,331 women were diagnosed with AF in England, Scotland, Wales, Northern Ireland, and the United Kingdom in 2017/18.
For More Information, Request Sample Copy Of Business Report: https://www.coherentmarketinsights.com/insight/request-pdf/3960
Furthermore, R&D to expand the application of heparin is also expected support growth of the market. For instance, Researchers from Chungbuk National University in South Korea announced in June 2020 that heparin-binding peptide may be used to treat rheumatoid arthritis.
Availability of alternative anticoagulants is expected to hamper growth of the market. Warfarin has long been the drug of choice for anticoagulant treatment around the world. Furthermore, new anticoagulants such as rivaroxaban, dabigatran, and apixaban are eating into heparin’s market share.
Furthermore, Heparin use can also cause an increase in serum aminotransferase, hyperkalemia, alopecia, and osteoporosis. As a result of these side effects, the market’s growth is expected to be limited.
Use of sharp-catching label to prevent needlestick injuries is expected to offer lucrative growth opportunities for players in Europe heparin market. For instance, on medical packaging, B. Braun Medical Inc.’s Heparin Sodium Injection USP prefilled syringes have a needle-securing label created by Schreiner MediPharm.
Furthermore, R&D in heparin mechanism is expected to lead to market expansion. Researchers from Martin Luther University Halle Wittenberg in Germany, for example, published a study in May 2020 that looked at the anti-inflammatory properties of surface coatings made of either hyaluronic acid or heparin in combination with chitosan prepared as multilayers using the layer-by-layer technique.
Europe heparin market was valued at US$ 2,698.7 Mn in 2019 and is forecast to reach a value of US$ 4,085.8 Mn by 2027 at a CAGR of 6.1% between 2020 and 2027.
Europe heparin market is estimated to account for US$ 4,085.8 Mn in terms of value by the end of 2027.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Exclusive offer!!! Purchase the report at a discounted rate!!!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Buy Now with Discount for Premium Report 2021: https://www.coherentmarketinsights.com/promo/buynow/3960
Germany is expected to witness significant growth in in Europe heparin market during the forecast period. It held a dominant position in 2019 accounting for 28.3% share in terms of volume.
France and UK are also expected to witness significant growth in Europe heparin market during the forecast period.
Market Trends/Key Takeaways:
Major players in the market witnessed significant sales growth. For instance, Laboratorios Farmaceuticos Rovi S A recorded a 42 percent increase in heparin franchise sales (LMWH and other heparins) to around US$ 60 million in the first quarter of 2020.
The effectiveness of heparin alternatives in the treatment of VTE is also being studied by major market players. For example, the Bristol-Myers Squibb-Pfizer alliance revealed in December 2019 that Eliquis use was associated with lower rates of major bleeding, clinically significant non-major bleeding, and recurrent VTE in patients with active cancer as compared to LMWH at American society of hermatology annual meeting.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/europe-heparin-market-3228
Major players operating in Europe heparin market include., Fresenius SE & Co. KGaA, Leap Labchem Co., LEO Pharma A/S, Sanofi S.A., Syntex S.A., Teva Pharmaceutical Industries Ltd., United Biotech (P) Ltd, Amphastar Pharmaceuticals Inc., Abbott Laboratories, Aspen Pharmacare Holdings, Pfizer, Inc., Sagent Pharmaceuticals, Inc., B. Braun Melsungen AG, Baxter International Inc., GlaxoSmithKline plc, Bayer AG, Anselm Pharmaceuticals, Bristol-Myers Squibb Co., Dr. Reddy’s Laboratories LtdLaboratorios Farmaceuticos ROVI SA, and Intrapharm Laboratories.
In April 2018, Laboratorios Farmaceúticos Rovi SA signed a license expanding agreement with Hikma Pharmaceuticals PLC for ROVI’s enoxaparin biosimilar.
Europe Heparin Market, By Product Type is segmented into:
- Low Molecular Weight Heparin
- Unfractionated Heparin
- Ultra Low Molecular Weight Heparin)
By End User:
- Blood and Stem Cell Bank
- Others (Laboratories, Acute Care Centers)
- North America
- Latin America
- Asia Pacific
- Middle East
Other Exclusive Reports:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027